


European Access Hurdles Portal & the Root Causes Analysis Smaller markets

Revised Country Analysis May 2025




Approach: We have followed a multi-step approach to understand the root causes of unavailability and delay in smaller markets



Approach: We have applied this framework to understand patterns of filing and availability in each smaller market

Why might there be delays in filing of a newly centrally approved medicine?



If MAHs lack a local presence in a smaller market, this can make it <u>impossible</u>, <u>impractical</u> or <u>unsustainable</u> for them to file a new medicine for P&R, depending on the local context and P&R requirements

Summary results: We find that the reasons for delays in filing in smaller markets are multi-faceted and driven by the local context

Relative importance of each factor in:	because it is <u>unnecessary</u> to file to obtain access	because local requirements make it <u>difficult</u> <u>or impossible</u> for the MAH to file	because features of the local system make it <u>impractical</u> to file	because it is <u>unsustainable</u> (the business case cannot be made) for the MAH to do so
Malta				
🥑 Cyprus		\bigcirc		
😑 Latvia				
📦 Lithuania				
Estonia				
i Slovenia	\bigcirc			
💿 Croatia	\bigcirc			
😵 N. Macedonia		\bigcirc		
Montenegro				

Why are there delays in filing of newly centrally approved medicines?

Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: MAH = marketing authorization holder

Relative importance (in the local context) of each potential argument for explaining the filing data

Kev:





In Malta, there is a low reimbursement rate (2%) of innovative medicines and a low filing rate (9%)



- Either MAHs or Medical Consultants can file for inclusion on the Government Formulary List (GFL)
- Pharmacists within the **DPA** compile **HTAs** including **clinical and budget impact** assessments for review by the GFLAC
- The GFLAC and ACHCB review outputs from the DPA an issue both technical and financial recommendations to the MoH on whether an innovative product should be included on the GFL

P&R overview

Alternative

access

(15%)

5

Along with the Minister for Finance, the Chief Medical Officer and Senior Health Officials, the MoH is responsible for setting out prioritization before the CPSU are responsible for procurement, negotiating with MAHs and issuing tenders

New perspective on Root Causes


- There are no direct barriers impacting the timing of filing in Malta, but in practice, payers reference the completed assessments and decisions 1. made in other European countries
- 2. The Maltese P&R system is chronically under-resourced, leading to delays in decision-making, budgetary constraints see specific therapy areas prioritized for procurement
- 3. There is a significant lack of transparency as to a product's status after filing and a significant backlog, discouraging filling
- The tenders are largely **single-winner**, **price-only** and lasting **3-4 years**, meaning innovative medicines can be frozen out of the public 4. reimbursement market
 - It is **not necessary for medicines** to have **<u>filed</u> and be listed on the GFL to bid for a tender, creating the** possibility for reimbursed patient access without filing and going through the standard reimbursement system
 - The Maltese Community Chest Fund offers public access for products which are not supplied via standard ٠ reimbursement route and does not require filing
 - The Exceptional Medicines Treatment Committee (EMTC) assess and approve medicines on a named patient ٠ basis for rare disease medicines not currently on the GFL

Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: ACHCB = Advisory Committee for Health Care Benefits; CPSU = Central Procurement Supply Unit; DPA = Directorate for Pharmaceutical Affairs; GFL = Government Formulary List; GFLAC = Government Formulary List Advisory Committee; HTA = health technology assessment



In Malta, it is not necessary to file a medicine for P&R in order to achieve broad patient access



Kev:

CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: CPSU = Central Procurement Supply Unit; P&R = pricing and reimbursement

6


<> = fairly reflected in Portal data

= underrepresented in Portal data

A



We expect that the impact of local filing requirements is underrepresented in the Portal data for Malta




Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Key: **1** = underrepresented in Portal data

e

A major issue impacting filing decisions in Malta is likely not being fully captured by the current options in the Portal




Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025) Abbreviations: P&R = pricing and reimbursement

Key:
 = underrepresented in Portal data
 = fairly reflected in Portal data

A

It is challenging for companies to make a reasonable business case to launch in Malta as a result of significant budget constraints

Malta




= fairly reflected in Portal data

Kev:

= underrepresented in Portal data

The raw Portal results for Malta will therefore need to be framed with a more nuanced description of the complex barriers to filing

Malta



Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: BI = budget impact; MAH = marketing authorization holder; P&R = pricing and reimbursement

10

Kev:

Relative importance (in the local context) of each potential argument for explaining the filing data



In Cyprus, there is a low reimbursement rate (1%) of innovative medicines and a low filing rate (20%)



Alternative

- Manufacturers must file for inclusion in the positive reimbursement list of the National Health System (GESY)
- The Medicines Advisory Committee (MAC) are then responsible for assessing the submissions; although clinical best
 practices are considered, the main focus is on the budget impact of the innovative product
- If the MAC recommends inclusion, the Medicines Reimbursement Advisory Committee (MRAC) will negotiate an acceptable price with the manufacturer for inclusion in the positive reimbursement list

New perspective on Root Causes


- 1. There are no **direct barriers** impacting the timing of filing in Cyprus, but in practice, payers reference the completed assessments and decisions made in other European countries
- 2. The MAC are **under-capacity** and have **complex guidelines**, including the need to develop Cyprus-specific therapeutic protocols for each product, contributing to **significant delays**, discouraging filling
- 3. There is a **lack of transparency** for MAHs on the progress of their product submission and indirect reference to reimbursement and HTA in other jurisdictions (the use of **Greece** as a key reference market results in **downward price pressure**)
- 4. Budget pressures are intense, the pharmaceutical expenditure budget **has not risen in line with a memorandum of understanding** with the industry, nor in line with the growth of GESY's total budget
- 5. Budget impact analyses are difficult to achieve without access to local epidemiological data, discouraging filing for orphan products
 - Until Jan 2025, a large proportion of innovative medicines were made available via the named-patient basis route at the MoH, which had funding of ~€100mn, did not require manufacturer filing, allowed higher prices and saw a shorter delay to patient access
 - access (27%) However, this route is **now under the control of GESY**, leaving the future uncertain

Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025) Abbreviations: GESY = National Health System; HTA = health technology assessment; MAC = Medicines Advisory Committee; MAH = marketing authorization holder; MoH = Ministry of Health; MRAC = Medicines Reimbursement Advisory Committee; P&R = pricing and reimbursement

11

Patients have access to more Portal products through alternative access schemes than products that have been formally filed for P&R

Cvprus



Kev:

Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)


12

= fairly reflected in Portal data

= underrepresented in Portal data

Informal filing requirements and small patient numbers can impact the speed of filing of new medicines

Cvprus



Kev

= underrepresented in Portal data


<> = fairly reflected in Portal data

CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: HIO = Health Insurance Organisation; IRP = international reference pricing; P&R = pricing and reimbursement

Introduction of the new P&R system has been a huge achievement, but initial backlogs may have disincentivised filing of new medicines

Cvprus




Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: P&R = pricing and reimbursement

= underrepresented in Portal data Kev: <> = fairly reflected in Portal data

The pharmaceutical budget has not grown in line with the growth of GESY's total healthcare budget

Cvprus



Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)


Abbreviations: GESY = National Health Service; MAH = marketing authorization holder

15

Key: 1 = underrepresented in Portal data
<> = fairly reflected in Portal data

The Portal data support that whilst navigating the new P&R process is challenging, many products are accessible through other means

Cvprus



Key:



Relative importance (in the local context) of each potential argument for explaining the filing data



In Latvia, there is a low reimbursement rate (10%) of innovative medicines and a low filing rate (29%)



- Any of the NHS*, the MAH, a wholesaler or a legal representative can file an innovative product for reimbursement The State Medicines Agency (SMA) are responsible for conducting HTA, which includes a clinical evaluation and a cost
 - effectiveness evaluation

Alternative

access (6%)

17

Following a SMA recommendation, the NHS are responsible for determining whether a product is **included in the positive** reimbursement list following application of prioritization criteria and negotiated price discounts

New perspective on Root Causes


- An inherent challenge in Latvia is the insufficient (and fluctuating) healthcare budget to procure all innovative medicines that the SMA 1. recommends; as a result, there is a permanent queue of innovative products waiting to receive reimbursement, which have had a positive assessment from the SMA for many years
- There are defined criteria for prioritizing which medicines in the queue to reimburse, but decisions can be politically driven in practice and prioritise certain therapy areas over others
- 3. The lack of **epidemiological information** in some therapy areas makes it difficult to conduct **budget impact analyses** when preparing a new dossier, or introduce innovative contracting beyond basic volume/price caps during negotiations
- There are **poorly developed alternative access schemes** for highly specialized, orphan and/or high-cost medicines 4.

Although a **named patient reimbursement** programme is available in Latvia for patients to access innovative • products which are not yet reimbursement, this is a small pathway (although budget is increasing) and is inefficiently designed, requiring approval by both the SMA and MoH with separate contracts negotiated per hospital

Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025) Abbreviations: HTA = health technology assessment; MAH = marketing authorization holder; MoH = Ministry of Health; NHS = National Health System; P&R = pricing and reimbursement; SMA = State Medicines Agency *The NHS can propose the reimbursement of older medicines that are deemed highly necessary by preparing a simplified dossier that does not require review by the SMA

In absence of substantive alternative access schemes to bridge the gap to patient access, filing for P&R is necessary for new medicines

Latvia




<> = fairly reflected in Portal data

Abbreviations: HTA = health technology assessment; P&R = pricing and reimbursement

For certain medicines, some companies may find it impossible to file if there are no useable local registries in that indication

Latvia




<> = fairly reflected in Portal data

Abbreviations: IRP = international reference pricing; P&R = pricing and reimbursement

19

The disconnect between positive HTA and timely reimbursement make it impractical for new medicines to be added to the queue

Latvia



Kev:

Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025); Evaluation of applications for inclusion of new drugs in the List of Reimbursable Drugs or expansion of reimbursement conditions (as of October 1, 2024)

Abbreviations: EMA = European Medicines Agency; HTA = health technology assessment

= fairly reflected in Portal data

= underrepresented in Portal data




The multi-faceted reasons for delays in filing in Latvia result in challenging commercial conditions for launching new medicines


Kev:

What does the Portal data tell us?





How can we interpret this considering our understanding of the market?



Abbreviations: MAH = marketing authorization holder


21

= fairly reflected in Portal data

= underrepresented in Portal data

The practicality of filing new medicines in Latvia is often a concern, particularly in therapy areas that are not prioritised by the government

Latvia



Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: HTA = health technology assessment; MAH = marketing authorization holder; NPP = named patient programme; P&R = pricing and reimbursement

22

Key:

Relative importance (in the local context) of each potential argument for explaining the filing data

In Lithuania, for products included in the Portal, there is a low reimbursement rate (7%) and a low filing rate (26%)



- MAHs file for reimbursement with the **State Medicine Control Agency** of Lithuania, who conduct an HTA by investigating comparative efficacy, comparative effectiveness and cost-effectiveness and produce a **public assessment report**
- The NHIF negotiate with manufacturers on the final price of innovative products and conduct budget impact analyses
- The Reimbursement Committee assess these reports and make a final decision on the outcome of a product; if successful a
 product moves to the positive-waiting list where it remains until budget becomes available to move to the positive list

New perspective on Root Causes

- 1. The current value assessment system is **complex**, leading to a lower likelihood of success if companies do not have **sufficient internal expertise** to navigate the system
- 2. It can be difficult for companies to prepare submissions for filing due to a **lack of available data** (e.g., epidemiological data), and because comparators used in pivotal trials may not reflect the Lithuanian SoC, contributing to low likelihood of success
 - a) As a result, medicines are often deemed not to be adding additional therapeutic value, in which case there are **strict pricing rules applied** (average of existing alternatives in that indication, **including generics**)
- 3. There is a **lack of flexibility** in the P&R system for companies and a lack of willingness from payers for companies to propose innovative access solutions to **deal with data immaturity or uncertainty** in the evidence package, leading to high likelihood of rejection for many drugs
- 4. There is an **insufficient budget to implement positive HTA decisions**, leading to products remaining on the positive-waiting list for years




23

- There is an **ultra-rare pathway**, whereby patients can receive access to drugs that treat diseases with an incidence of 1 per 200,000 on a named-patient basis following a request by the physician/PAG and an assessment by the Committee for the reimbursement of ultra-rare diseases
- The **methodology for this assessment is not transparent** and decisions can often be **politically influenced**, leading to unpredictability for companies

Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025) Abbreviations: HTA = health technology assessment; MAH = marketing authorization holder; NHIF = National Health Insurance Fund; PAG = patient advocacy group; P&R = pricing and reimbursement; SoC = standard of care



Filing for the standard pricing and reimbursement evaluation is necessary for most medicines to obtain patient access




<> = fairly reflected in Portal data

Abbreviations: HTA = health technology assessment; NPP = named patient reimbursement; PAG = patient advocacy group; P&R = pricing and reimbursement

24

Filing can be delayed as a result of MAHs not being able to access data or because of payer preference to reference completed HTAs

Lithuania



Kev:

= underrepresented in Portal data

<> = fairly reflected in Portal data


Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: HTA = health technology assessment; MAH = marketing authorization holder

25

The major barrier to filing in Lithuania is practicality; the P&R system is highly complex, and it is challenging to achieve reimbursement


Lithuania




Key: **1** = underrepresented in Portal data

<> = fairly reflected in Portal data

P






Lithuania

Key: **1** = underrepresented in Portal data

P

The Lithuanian P&R system is complex and requires the Portal data to be interpreted with a nuanced, country-specific approach

Lithuania



Key:



Relative importance (in the local context) of each potential argument for explaining the filing data

In Estonia, for products included in the Portal, there is a moderately low reimbursement rate (25%) and filing rate (38%)



The EHIF manages reimbursement of new medicines through a positive list of medicines and healthcare services. The list is
updated 4x per year, although applications for the list of services can be submitted 1x per year

Estonia

• MAHs or HCP associations can file for inclusion of a product on this list, following which HTA is carried out



29

There are **service lists** which set price and reimbursement conditions for classes of drugs; generic and biosimilar products can be included in these lists **without filing for P&R**. Innovative products part of the same class can achieve reimbursement through an abridged process, whereby they do not need to submit CEA and it is **sufficient to show budget neutrality**


New perspective on Root Causes

- 1. The **ICER thresholds applied to innovative medicines are low** compared to other countries (including neighboring Baltic countries) and are challenging for innovative medicines to meet (exacerbated by VAT rate being considered in the calculation)
 - a) Strict reimbursement restrictions are frequently applied to medicines as a result of the ICER thresholds
- 2. After a positive HTA and reimbursement decision, medicines are **included quarterly into the positive reimbursement list**
- 3. Estonia has the smallest population size of the Baltic states (1.3 million people); combined with the challenging pricing conditions, this makes it **challenging to make a viable business case** to launch a new medicine in certain contexts (e.g. for rare diseases, or for smaller companies)
- 4. There are **limited alternative access schemes**, with individual patient-based reimbursement available only for non-registered medicines following a HCP application. In practice, this is rarely used

RA	Outside of the standard process, there are no alternative routes for widespread patient access
, ľ	• Charity Estonian Children's Funds offer privately initiated cancer treatment for infants via private charity funds (i.e., 'The Gift of Life')
Alternative access (4%)	 Named patient reimbursement is possible mainly for non-registered medicines if HCPs can make a case to the EHIF, although criteria is clear for acceptance, the decision on reimbursement may vary




It is not necessary for MAHs to file all new medicines for P&R evaluation in Estonia in order to achieve reimbursement



30

Historically it has not always been possible for MAHs to file for P&R, which has likely affected some medicines in the Portal

Estonia



Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: MAH = marketing authorization holder; P&R = pricing and reimbursement

31


<> = fairly reflected in Portal data

Kev

= underrepresented in Portal data

e

Many medicines cannot meet the ICER thresholds; this makes it impractical to waste MAH and EHIF resources on a lengthy evaluation



Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: EHIF = Estonian Health Insurance Fund; ICER = incremental costeffectiveness ratio; MAH = marketing authorization holder; P&R = pricing and reimbursement

32

Key: **1** = underrepresented in Portal data **<>** = fairly reflected in Portal data




Estonia

The small size of Estonia and the low per capita spend on healthcare makes it a challenging commercial environment for companies

= underrepresented in Portal data

<> = fairly reflected in Portal data



Kev:

Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: EHIF = Estonian Health Insurance Fund: MAH = marketing authorization holder; P&R = pricing and reimbursement


33

How can we interpret this considering our understanding of the market?

Estonia



It is not necessary for all medicines to file for P&R to achieve reimbursement; where it is necessary, it is often not practical to file



Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: EHIF = Estonian Health Insurance Fund; HTA = health technology assessment; ICER = incremental cost-effectiveness ratio; MAH = marketing authorization holder; P&R = pricing and reimbursement

34

Key:



Relative importance (in the local context) of each potential argument for explaining the filing data





In Slovenia, for products included in the Portal, there is a moderate filing rate overall (56%), but this is lower for OMPs and ATMPs



- After MA, the manufacturer applies to the JAZMP to determine its **Maximum Allowed Price (MAP)** via **international reference pricing** where the MAP cannot exceed the lowest price of a product in Austria, France or Germany
- The ZZZS will conduct a **clinical assessment** and, if successful, will enter into **negotiations** with the manufacturer. ZZZS will use **the current cost of drugs** in the **respective therapeutic area** as a starting point and **MEAs** are common for oncology, orphan and ATMP medicines. If successful a product will be places on a **positive list for reimbursement**

New perspective on Root Causes

- 1. Although the requirements for local BI and CE analysis in P&R dossiers are clear, the dossier development can be challenging, especially for small affiliate teams and companies without a local presence, due to difficulties **sourcing local data** and the possible need to hire a local vendor
- 2. Historically, the ZZZS have lacked sufficient resources for timely assessment and negotiations, leading to some delays (e.g. months between a positive reimbursement decision and the beginning of price negotiations). However, ZZZS have increased headcount recently and made progress in clearing the P&R backlogs in 2024, with strong time to access compared to other CEE countries
- 3. There are variable objective criteria for the assessment of P&R applications by the ZZZS; this can support the availability of new medicines by offering different negotiation possibilities (e.g., negotiating on a particular product or across a portfolio), but also h inder availability (as it creates an uncertain operating environment for MAHs and could lead to a proposed price decrease for other portfolio medicines)
- 4. There are limited alternative access opportunities, leading to difficulties in launching certain products (e.g., rare diseases)
 - Previously, the **EHAP pathway** granted manufacturers a higher list price for innovative products, mitigating any internal concerns on IRP and launch sequencing. However, the JAZMP has reduced use of this pathway for innovative products and uses it mainly for securing the supply of older medicines

Alternative access (4%)


35

- There is an **unfunded CUP** to provide access **pre-regulatory approval** and a **named-patient program**, funded by ZZZS to **support patient access pre-reimbursement**
- Hospitals can also purchase medicines directly from their budget

Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: ATMP = advanced therapy medicinal product; BI = budget impact; CE = cost-effectiveness; CUP = compassionate use programme; EHAP = Exceptional Higher Allowed Price; JAZMP = Agency for Medicinal Products and Medicial Devices; MA = marketing authorization; MAP = maximum allowed price; OMP = orphan medicinal product; ZZZS = Health Insurance Institute of Slovenia;

All medicines must file for P&R to achieve reimbursement, but ambiguity in the process and a low population deters MAHs



Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: P&R – Pricing & Reimbursement; MAH – Marketing Authorisation Holder; MAP – Maximal Allowed Price

36

Kev:

Relative importance (in the local context) of each potential argument for explaining the filing data

efpia CRA^{Charl}

Slovenia



In Croatia, for products included in the Portal, there is a moderate filing rate overall (44%), but this is lower for rare and oncology drugs



- After MA, the manufacturer applies to HALMED to determine the maximum permissible wholesale price via international reference pricing where the price is usually the average of prices in Italy, Slovenia and Czechia*
- HZZO are then responsible for determining whether a product should be placed on the reimbursement list; the MPC make
 decisions based on specified reimbursement criteria, which are confirmed by the Governing Council

P&R overview

Reimbursement negotiations involve the agreement on a **financial MEA** between the MAH and the HZZO (typically a valuecap agreement) **established at an indication level** (primarily for medicines on the list of especially expensive drugs)

New perspective on Root Causes

- 1. The price setting process is often timely (concluded within 30 days), but the subsequent reimbursement decision can take **between 6 months and 3 years**, with minimal communication to the MAH
- 2. More generally, there are political considerations in the appointment of the Drugs Committee and there is a **lack of transparency in how P&R regulations are interpreted by HZZO**, with many reasons for rejections either lacking specific objective feedback, or citing opaque factors
- 3. Once a medicine is included on the primary drugs list, all patients will have a **guaranteed access to the medicine**, but the full potential of treated patients would not be exceeded due to **hospital budget restrictions**. The **Special Fund** for expensive drugs was **established** as a source of funding outside hospital budgets to address this
- 4. Criteria on access on **Special Fund For Expensive Drugs (SFED)** are defined in 2023 Ordinance, but not always obeyed and are often **misinterpreted by the Payer**. There are no definitions on alternative funding processes beyond the basic drugs list and SFED

Alternative access (6%)


- During the negotiation process, HZZO can decide to include new medicines on the list of "especially expensive drugs", with the list favoring drugs for unmet need (rare diseases, early line oncology and haematology), and a separate national budget (SFED) allocated for reimbursement of these high-cost products
- An unfunded EAP allows access between EMA approval and Croatian reimbursement decisions

*where list prices are unavailable in reference countries, protocols are in place to ensure there is no delay resulting from the price setting stage

Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025) Abbreviations: HALMED = Croatian Agency for Medicinal Products and Medical Devices; HZZO = Croatian Health Insurance Fund; MAH = marketing authorization holder; MPC = Medicinal Products Committee



A P&R system geared towards cost-containment and negative reimbursement outcomes presents significant challenge to filing



Sources: European Access Hurdles Portal data collection cycle 6 (N=94 products); CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: EAP – Early Access Program, HZZO - Croatian Health Insurance Fund, MEA – Managed Entry Agreement

38



Relative importance (in the local context) of each potential argument for explaining the filing data



In North Macedonia, there is low availability (8%) of innovative medicines



- MALMED are responsible for regulatory approval of innovative products; although there is no automatic recognition of EMA decisions, manufacturers can submit largely the same dossier and there is fast approval if already centrally approved
- The National Pharmaceutical Pricing Authority, sitting within the MoH, set the maximum price using **IRP once per year**, taking the average of the **two lowest prices** within **Bulgaria**, **Croatia**, **Greece**, **Serbia** and **Slovenia**
- A committee within the MoH will then make a decision on reimbursement, including a clinical evaluation via a scoring system and KOL representation. If reimbursed, the budget must then be confirmed by the NHIF, who conduct a second round of IRP (at least once per year; taking the average of the two lowest from the same countries except Greece)

P&R overview

Alternative

access

Hospital products then need to be requested and procured by individual clinics via tenders

New perspective on Root Causes


- 1. The price setting system in North Macedonia is **restrictive**, with **two rounds of IRP** reducing the maximum price possible for innovative products. This reflects the wider environment of **insufficient funding for innovative products**
- 2. Following this, initially the **reimbursement list is not updated in a timely manner** and then the use of **tenders for innovative medicines** further constrains prices and delays patient access
- 3. Overall, the P&R process is **complex**, **bureaucratic** and **time-consuming**, making it difficult for manufacturers to achieve reimbursement and for clinics to gain access to new medicines; this is exacerbated by **many companies working through distributors**, rather than having a local presence
- 4. There is **insufficient infrastructure** outside of major cities to provide patient access to innovative medicines, affecting some therapy areas more than others
- 5. There is a **lack of synchronization** between the **reimbursement** and **pricing decisions**, for example, MEAs can be negotiated in theory, but they are disconnected with the reimbursement decision, so companies do not currently apply as it does not help to enable patient access
 - Rare diseases go through an **alternative access scheme** via the **National Committee for Rare diseases**, with specific funding coming form an **alcohol and tobacco tax.** Although this works well, access is endangered by **yearly tenders**

A conditional funding mechanism allows reimbursement as separate from the standard process if this is requested by major clinics, with ~60 innovative medicines currently on this list due to faster access and greater flexibility shown by HIF

Sources: EFPIA Patients W.A.I.T. Indicator 2024 Survey; CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: IRP = international reference pricing; KOL = key opinion leader; MALMED = Agency for Medicines and Medical Devices of the Republic of North Macedonia; MEA = managed entry agreement; NHIF – National Health Insurance Fund

Clinician-led conditional funding requests play an important role in enabling patient access in addition to the standard P&R process



Sources: CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025) Abbreviations: IRP = international reference pricing; MAH = marketing authorization

holder; P&R = pricing and reimbursement



Relative importance (in the local context) of each potential argument for explaining the filing data

40



In Montenegro, there have been recent efforts to strengthen the P&R process, but some access barriers remain



- Manufacturers can only submit applications for national marketing authorization after EC decision; CINMED are responsible for regulatory approval decisions, and they review applications in line with the EMA's methodology for assessments with a timeline of 150 days
- CINMED are then responsible for determining the maximum wholesale price using IRP, taking the average price of Czechia, Romania and Serbia (if no prices are available, the reference price is the lowest of the EU Member States)

P&R overview

Alternative

access


41

• A reimbursement commission (comprised of clinicians, health economists, **HIF** and **MOH** representatives) is then responsible for determining which medicines are included on the **positive reimbursement list**; then these are procured via tenders

New perspective on Root Causes

- The process for registering a new medicine in Montenegro typically only begins after EMA approval (to leverage efficiencies from the dossier and published decision from the centralized European process); marketing authorization therefore typically happens later (~1 year) in Montenegro than in the EU
- 2. The **frequency of updates to the positive list** were previously unpredictable and varied across years; new regulations have improved consistency of this process (three updates per year), but this may affect historical patterns on unavailability and delays
- 3. The **decision-making process** for updates to the positive list remain **opaque and constrained by insufficient budget**; lack of budget availability has led to a backlog of medicines awaiting inclusion in the list (with no ability to track where medicines are in the process) and unclear reasons for rejection of applications
- 4. It is **not possible to negotiate MEAs** to support introduction of new medicines as there is not sufficient data infrastructure to implement these, instead, all new innovative products are subject to a financial discount decided during a **Special Agreement** during the negotiation process
 - Clinicians can request named patient reimbursement for rare disease therapies by applying to the Ministry
 of Health. This can accelerate patient access, but access is less predictable and sustainable than the standard
 P&R process (as approvals are typically given for a three-month period before being re-reviewed)
 - This pathway is **relatively new** (established ~4 years ago)
- Sources: CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025) Abbreviations: CALIMS = Agency for Medicines and Medical Devices; CInMED = Institute for Medicines and Medical Devices; HIF = Health Insurance Fund of Montenegro

Reimbursement backlogs and lack of ability to implement innovative access solutions can impede access to some medicines



Sources: CRA literature review and interviews with pharmaceutical companies and trade associations (conducted Dec 2024-Feb 2025)

Abbreviations: IRP = international reference pricing; MAH = marketing authorization holder; P&R = pricing and reimbursement

42



Relative importance (in the local context) of each potential argument for explaining the filing data

